Diagnostic and biological significance of microRNA-192 in pancreatic ductal adenocarcinoma

Zhao,Chenyan; Zhang,Jing; Zhang,Shuhui; Yu,Danghui; Chen,Ying; Liu,Qinghua; Shi,Min; Ni,Canrong; Zhu,Minghua

doi:10.3892/or.2013.2420

Diagnostic and biological significance of microRNA-192 in pancreatic ductal adenocarcinoma

Authors:
- Chenyan Zhao
- Jing Zhang
- Shuhui Zhang
- Danghui Yu
- Ying Chen
- Qinghua Liu
- Min Shi
- Canrong Ni
- Minghua Zhu
View Affiliations

Affiliations: Department of Pathology, Changhai Hospital, Second Military Medical University, Shanghai, P.R. China
Published online on: April 23, 2013 https://doi.org/10.3892/or.2013.2420
Pages: 276-284

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal types of human cancer. In the present study, we evaluated serum microRNA-192 (miR-192) as a potential biomarker in patients with PDAC and investigated its biological functions in this disease. miRNA expression profiling of human PDACs and adjacent normal pancreatic tissues identified 16 upregulated miRNAs including miR-192 and 8 downregulated miRNAs. Quantitative real-time polymerase chain reaction (PCR) revealed elevation of serum miR-192 levels in PDAC patients relative to these levels in duodenal adenocarcinoma patients and healthy controls. Receiver operating characteristic analysis demonstrated that serum miR-192 had a sensitivity of 76% and a specificity of 55% for detecting PDAC. Ectopic expression of miR-192 in PANC-1 pancreatic cancer cells enhanced cell proliferation and migration, reduced apoptosis and promoted cell cycle progression from the G0/G1 to the S phase. Western blot analysis showed that enforced expression of miR-192 decreased the expression of smad-interacting protein 1 (SIP1) and altered a set of cell cycle-related genes in the PANC-1 cells. miR-192 overexpression increased tumor volume in an orthotopic pancreatic cancer mouse model, coupled with suppression of SIP1 and elevation of collagen I. In conclusion, serum miR-192 may serve as a sensitive diagnostic biomarker for PDAC. Overexpression of miR-192 contributes to tumor growth and progression in PDAC, which is associated with repression of SIP1 and alteration of cell cycle regulatory genes.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
2	Li D, Xie K, Wolff R and Abbruzzese JL: Pancreatic cancer. Lancet. 363:1049–1057. 2004. View Article : Google Scholar
3	Brand RE and Matamoros A: Imaging techniques in the evaluation of adenocarcinoma of the pancreas. Dig Dis. 16:242–252. 1998. View Article : Google Scholar : PubMed/NCBI
4	Goonetilleke KS and Siriwardena AK: Systematic review of carbohydrate antigen (CA 19–9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 33:266–270. 2007.PubMed/NCBI
5	Kawai S, Suzuki K, Nishio K, et al: Smoking and serum CA19–9 levels according to Lewis and secretor genotypes. Int J Cancer. 123:2880–2884. 2008.
6	Koopmann J, Rosenzweig CN, Zhang Z, et al: Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19–9. Clin Cancer Res. 12:442–446. 2006.PubMed/NCBI
7	Bünger S, Laubert T, Roblick UJ and Habermann JK: Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview. J Cancer Res Clin Oncol. 137:375–389. 2011.PubMed/NCBI
8	Cortez MA, Welsh JW and Calin GA: Circulating microRNAs as noninvasive biomarkers in breast cancer. Recent Results Cancer Res. 195:151–161. 2012. View Article : Google Scholar : PubMed/NCBI
9	Redova M, Poprach A, Nekvindova J, et al: Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med. 10:552012. View Article : Google Scholar : PubMed/NCBI
10	Jung DE, Wen J, Oh T and Song SY: Differentially expressed microRNAs in pancreatic cancer stem cells. Pancreas. 40:1180–1187. 2011. View Article : Google Scholar : PubMed/NCBI
11	Keller A, Leidinger P, Gislefoss R, et al: Stable serum miRNA profiles as potential tool for non-invasive lung cancer diagnosis. RNA Biol. 8:506–516. 2011. View Article : Google Scholar : PubMed/NCBI
12	Mitchell PS, Parkin RK, Kroh EM, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
13	Mees ST, Mardin WA, Wendel C, et al: EP300 - a miRNA-regulated metastasis suppressor gene in ductal adenocarcinomas of the pancreas. Int J Cancer. 126:114–124. 2010. View Article : Google Scholar : PubMed/NCBI
14	Wang J, Chen J, Chang P, et al: MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res. 2:807–813. 2009. View Article : Google Scholar : PubMed/NCBI
15	Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ and Lötvall JO: Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 9:654–659. 2007. View Article : Google Scholar : PubMed/NCBI
16	Rabinowits G, Gercel-Taylor C, Day JM, Taylor DD and Kloecker GH: Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer. 10:42–46. 2009. View Article : Google Scholar : PubMed/NCBI
17	Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y and Ochiya T: Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem. 285:17442–17452. 2010. View Article : Google Scholar : PubMed/NCBI
18	Song B, Wang Y, Kudo K, Gavin EJ, Xi Y and Ju J: miR-192 regulates dihydrofolate reductase and cellular proliferation through the p53-microRNA circuit. Clin Cancer Res. 14:8080–8086. 2008. View Article : Google Scholar : PubMed/NCBI
19	Feng S, Cong S, Zhang X, et al: MicroRNA-192 targeting retinoblastoma 1 inhibits cell proliferation and induces cell apoptosis in lung cancer cells. Nucleic Acids Res. 39:6669–6678. 2011. View Article : Google Scholar : PubMed/NCBI
20	Vermeulen K, Van Bockstaele DR and Berneman ZN: The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 36:131–149. 2003. View Article : Google Scholar : PubMed/NCBI
21	Classon M, Salama S, Gorka C, Mulloy R, Braun P and Harlow E: Combinatorial roles for pRB, p107, and p130 in E2F-mediated cell cycle control. Proc Natl Acad Sci USA. 97:10820–10825. 2000. View Article : Google Scholar : PubMed/NCBI
22	Frescas D and Pagano M: Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer. 8:438–449. 2008. View Article : Google Scholar : PubMed/NCBI
23	Braun CJ, Zhang X, Savelyeva I, et al: p53-Responsive microRNAs 192 and 215 are capable of inducing cell cycle arrest. Cancer Res. 68:10094–10104. 2008. View Article : Google Scholar : PubMed/NCBI
24	Cloonan N, Brown MK, Steptoe AL, et al: The miR-17–5p microRNA is a key regulator of the G1/S phase cell cycle transition. Genome Biol. 9:R1272008.
25	Lim LP, Lau NC, Garrett-Engele P, et al: Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 433:769–773. 2005. View Article : Google Scholar : PubMed/NCBI
26	Georges SA, Biery MC, Kim SY, et al: Coordinated regulation of cell cycle transcripts by p53-inducible microRNAs, miR-192 and miR-215. Cancer Res. 68:10105–10112. 2008. View Article : Google Scholar : PubMed/NCBI
27	Zhang S, Hao J, Xie F, et al: Downregulation of miR-132 by promoter methylation contributes to pancreatic cancer development. Carcinogenesis. 32:1183–1189. 2011. View Article : Google Scholar : PubMed/NCBI
28	Katoh M and Katoh M: Integrative genomic analyses of ZEB2: Transcriptional regulation of ZEB2 based on SMADs, ETS1, HIF1α, POU/OCT, and NF-κB. Int J Oncol. 34:1737–1742. 2009.PubMed/NCBI
29	Mejlvang J, Kriajevska M, Vandewalle C, et al: Direct repression of cyclin D1 by SIP1 attenuates cell cycle progression in cells undergoing an epithelial mesenchymal transition. Mol Biol Cell. 18:4615–4624. 2007. View Article : Google Scholar : PubMed/NCBI
30	Sayan AE, Griffiths TR, Pal R, et al: SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer. Proc Natl Acad Sci USA. 106:14884–14889. 2009. View Article : Google Scholar : PubMed/NCBI
31	Grzesiak JJ and Bouvet M: The alpha2beta1 integrin mediates the malignant phenotype on type I collagen in pancreatic cancer cell lines. Br J Cancer. 94:1311–1319. 2006. View Article : Google Scholar : PubMed/NCBI
32	Menke A, Philippi C, Vogelmann R, et al: Down-regulation of E-cadherin gene expression by collagen type I and type III in pancreatic cancer cell lines. Cancer Res. 61:3508–3517. 2001.PubMed/NCBI
33	Imamichi Y, König A, Gress T and Menke A: Collagen type I-induced Smad-interacting protein 1 expression downregulates E-cadherin in pancreatic cancer. Oncogene. 26:2381–2385. 2007. View Article : Google Scholar : PubMed/NCBI